Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology

Building Your Care Team: Specialists and Vetting Questions

At a Glance

Treating Immune-Mediated Necrotizing Myopathy (IMNM) requires a multidisciplinary care team usually led by a neurologist and rheumatologist. Because the disease is rare, it is vital to find specialists experienced with IMNM who are willing to use aggressive immunosuppressive therapies.

Because Immune-Mediated Necrotizing Myopathy (IMNM) is both rare and multi-systemic, it requires a “team captain” and several specialized “players.” No single doctor can manage the complexities of the immune attack, muscle regeneration, and potential risks to your heart and lungs [1][2]. Your goal is to assemble a multidisciplinary team—a group of specialists who communicate with each other to manage your care holistically [3][1].

The Core Specialists

These are the primary doctors you will see most frequently to manage the disease itself.

  • Neuromuscular Specialist (Neurologist): Often the first to diagnose you, this doctor specializes in the relationship between nerves and muscles [4]. They interpret your Electromyography (EMG), oversee your muscle biopsy, and monitor your muscle strength [5][6].
  • Rheumatologist: This doctor is an expert in the immune system. Because IMNM requires aggressive immunosuppressive therapy, the rheumatologist often manages your medications (like steroids, methotrexate, or rituximab) and monitors your blood work for side effects [1][7].
  • Physical Therapist (PT): A PT specialized in myopathy is essential for your functional recovery [8]. They help you rebuild muscle through structured, safe exercise programs that avoid over-exertion while promoting “structural” repair of the muscle fibers [9][10].

The Support Specialists

Depending on your subtype and symptoms, you may need these specialists to monitor “silent” risks.

  • Cardiologist: Needed to monitor for cardiomyopathy or arrhythmias (irregular heartbeats), which can occur if the immune system attacks the heart muscle [11][2].
  • Pulmonologist: If you experience shortness of breath or have the anti-SRP subtype, a pulmonologist will monitor for Interstitial Lung Disease (ILD) or weakness in the respiratory muscles [2][12].
  • Oncologist: Particularly for seronegative or anti-HMGCR patients, an oncologist may be involved to perform a thorough “malignancy screen” to rule out cancer as an underlying trigger for the disease [13][14].

Vetting Your Team

IMNM is so rare that many general specialists may have only read about it in a textbook. To ensure you are receiving the highest standard of care, it is important to “audit” your care team’s experience [1].

  • Expertise in Rarity: Ask your doctor how many cases of IMNM they have treated in the last year. Ideally, you want a physician who has experience with this specific diagnosis, not just “general inflammation” [1][4].
  • Knowledge of Guidelines: An expert doctor should be familiar with the 2016 ENMC criteria, which are the international gold standard for diagnosing and subtyping IMNM [4][15].
  • Aggressive Stance: Because IMNM can cause permanent damage quickly, your doctor should be comfortable using aggressive combination therapies (like starting steroids and IVIG or methotrexate at the same time) rather than a “wait and see” approach [16][17].
  • Side Effect Management: Your team should have a clear protocol for monitoring the severe side effects associated with immunosuppression, including infection risk and metabolic changes [18][19].

Coordinating Your Care

A common challenge in rare disease is “fragmented care,” where one doctor doesn’t know what the other is doing. Ensure that your Rheumatologist and Neurologist are sharing notes and that there is a clear “lead” physician who is ultimately responsible for your overall treatment strategy [1][3].

Common questions in this guide

Which doctors treat Immune-Mediated Necrotizing Myopathy (IMNM)?
An IMNM care team is typically led by a neurologist and a rheumatologist. Depending on your specific symptoms and subtype, you may also need a physical therapist, cardiologist, pulmonologist, and oncologist to manage specific risks.
How do I know if my doctor is experienced with IMNM?
Ask your doctor how many cases of IMNM they have treated recently and if they use the 2016 ENMC diagnostic criteria. An experienced specialist should be comfortable using aggressive combination therapies rather than a wait-and-see approach.
Why do I need a rheumatologist for a muscle disease?
Because IMNM is an autoimmune disease, a rheumatologist is needed to manage the complex immunosuppressive medications. These drugs are required to stop the immune system from attacking your muscles and to prevent permanent damage.
What should I ask my doctor about IMNM treatments?
You should ask about their specific protocols for monitoring side effects like infection risk and metabolic changes. It is also important to ask if they are willing to use aggressive combination therapies if your symptoms do not improve quickly.
Why might an IMNM patient need to see an oncologist?
In some subtypes of IMNM, particularly seronegative or anti-HMGCR forms, the disease can be triggered by an underlying cancer. An oncologist may perform a malignancy screen to rule out cancer as the root cause.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with IMNM specifically (not just general myositis) do you currently manage?
  2. 2.Which diagnostic criteria do you use to classify IMNM, and are you familiar with the 2016 ENMC guidelines?
  3. 3.What is your specific protocol for monitoring and managing the severe side effects (like infection risk and metabolic changes) of aggressive immunosuppression?
  4. 4.Are you willing to use 'aggressive combination therapy' (like adding IVIG or methotrexate to steroids) immediately if my symptoms or CK levels don't improve?
  5. 5.Who will be the 'lead' physician on my team to coordinate between my heart, lung, and muscle specialists?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Statin-Associated Immune-Mediated Necrotizing Myopathy With Dual Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (Anti-HMGCR) and Anti-OJ Positivity: A Case Report of Fulminant Weakness and Respiratory Failure.

    Rahman MA, John D, Khan T, et al.

    Cureus 2025; (17(11)):e96123 doi:10.7759/cureus.96123.

    PMID: 41200259
  2. 2

    Cardiac and Respiratory Complications of Necrotizing Autoimmune Myopathy.

    Triplett J, Kassardjian CD, Liewluck T, et al.

    Mayo Clinic proceedings 2020; (95(10)):2144-2149 doi:10.1016/j.mayocp.2020.03.032.

    PMID: 32807522
  3. 3

    Tuberculosis-Induced Immune-Mediated Necrotizing Myopathy: A Challenging Case Scenario in a Non-Endemic Country.

    Colpani A, Astorri D, De Vito A, et al.

    Reports (MDPI) 2024; (7(4)) doi:10.3390/reports7040082.

    PMID: 40757675
  4. 4

    Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

    Allenbach Y, Benveniste O, Stenzel W, Boyer O

    Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

    PMID: 33093664
  5. 5

    Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: Possible double trouble.

    Tanboon J, Sanmaneechai O, Charuvanij S, et al.

    Neuromuscular disorders : NMD 2019; (29(7)):543-548 doi:10.1016/j.nmd.2019.05.007.

    PMID: 31204143
  6. 6

    Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia.

    Triplett JD, Shelly S, Livne G, et al.

    Brain communications 2020; (2(2)):fcaa191 doi:10.1093/braincomms/fcaa191.

    PMID: 33364599
  7. 7

    Statin-Related Necrotizing Autoimmune Myositis: More Than Myalgia.

    Scheuing WJ, Dadhania FB, Bankole AA

    Cureus 2022; (14(2)):e22654 doi:10.7759/cureus.22654.

    PMID: 35371630
  8. 8

    INPATIENT REHABILITATION AND FUNCTIONAL OUTCOME OF A CASE OF ANTI-SRP IMMUNE-MEDIATED NECROTIZING MYOPATHY.

    Chen N, Yamin Thein K, San Tay S

    Journal of rehabilitation medicine. Clinical communications 2024; (7()):40653 doi:10.2340/jrm-cc.v7.40653.

    PMID: 39444782
  9. 9

    Physical therapy in adult inflammatory myopathy patients: a systematic review.

    Van Thillo A, Vulsteke JB, Van Assche D, et al.

    Clinical rheumatology 2019; (38(8)):2039-2051 doi:10.1007/s10067-019-04571-9.

    PMID: 31115788
  10. 10

    Epidemiology of Dermatomyositis and Other Idiopathic Inflammatory Myopathies in Northern Spain.

    Corrales-Selaya C, Prieto-Peña D, Martínez-López D, et al.

    Biomedicines 2025; (13(10)) doi:10.3390/biomedicines13102537.

    PMID: 41153817
  11. 11

    Necrotizing myopathy presenting as congestive heart failure and life-threatening ventricular arrhythmias: a case report.

    Lim K, Park JS, Yoon BA, Han SH

    European heart journal. Case reports 2021; (5(6)):ytab075 doi:10.1093/ehjcr/ytab075.

    PMID: 34142007
  12. 12

    An Autopsy Case of Antibody-negative Immune-mediated Necrotizing Myopathy with Severe Cardiac Involvement.

    Tamura T, Miyajima K, Watanabe K, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(19)):3113-3119 doi:10.2169/internalmedicine.6355-20.

    PMID: 33840691
  13. 13

    Paraneoplastic anti-SRP antibody positive immune-mediated necrotizing myopathy in a young female associated with lymphoma.

    Heugenhauser J, Pauli FD, Stockhammer G, et al.

    Journal of neuromuscular diseases 2025; (12(4)):567-574 doi:10.1177/22143602251327002.

    PMID: 40266663
  14. 14

    A case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive paraneoplastic necrotizing myopathy associated with advanced gastric cancer that responded to intravenous immunoglobulin therapy.

    Yamaguchi T, Matsunaga A, Ikawa M, et al.

    Rinsho shinkeigaku = Clinical neurology 2017; (57(3)):118-123 doi:10.5692/clinicalneurol.cn-000982.

    PMID: 28228619
  15. 15

    Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

    Allenbach Y, Benveniste O

    Current opinion in rheumatology 2018; (30(6)):655-663 doi:10.1097/BOR.0000000000000547.

    PMID: 30239349
  16. 16

    Statin-Associated Autoimmune Myopathy: Review of the Literature.

    Barrons R

    Journal of pharmacy practice 2023; (36(2)):383-393 doi:10.1177/08971900211040291.

    PMID: 35707933
  17. 17

    Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes.

    Vaezi Z, Amini A

    Cureus 2025; (17(11)):e97933 doi:10.7759/cureus.97933.

    PMID: 41458822
  18. 18

    Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab.

    Zhang W, Prince HM, Reardon K

    BMJ case reports 2019; (12(11)) doi:10.1136/bcr-2019-232406.

    PMID: 31791994
  19. 19

    Autoimmune Myopathies: Updates on Evaluation and Treatment.

    McGrath ER, Doughty CT, Amato AA

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):976-994 doi:10.1007/s13311-018-00676-2.

    PMID: 30341597

This page provides educational information on building an IMNM care team. It is not a substitute for professional medical advice, diagnosis, or treatment.

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.